Cellectar Biosciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

FAIR VALUE (Details 1) (USD $)	3 Months Ended		9 Months Ended
FAIR VALUE (Details 1) (USD $)	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value of warrants issued in connection with February 2013 public offering			$ 4,102,709	$ 5,720,000
Gain on derivatives resulting from change in fair value	2,850,171	1,597,372	3,368,977	2,263,756
Fair Value, Inputs, Level 3 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance - Fair value			3,355,000	0
Fair value of warrants issued in connection with February 2013 public offering			0	5,720,000
Gain on derivatives resulting from change in fair value			(2,535,500)	(2,365,000)
Ending balance - Fair value	$ 819,500	$ 3,355,000	$ 819,500	$ 3,355,000